Health Care & Life Sciences » Pharmaceuticals | Walvax Biotechnology Co. Ltd.

Walvax Biotechnology Co. Ltd. | Mutual Funds

Mutual Funds that own Walvax Biotechnology Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
5,463,561
0.44%
0
5.03%
12/31/2017
E Fund Growth Enterprise Index ETF
5,371,596
0.43%
311,300
2.78%
12/31/2017
4,698,662
0.38%
-908,936
2.31%
12/31/2017
4,369,798
0.35%
4,369,798
7.94%
12/31/2017
3,869,662
0.31%
-2,638,407
11.33%
12/31/2017
Huashang Prosperous Growth Fund
3,000,000
0.24%
-3,602,493
2.46%
12/31/2017
2,663,240
0.22%
2,663,240
1.84%
12/31/2017
2,465,071
0.2%
2,465,071
2%
12/31/2017
Chang Xin Zeng Li Fund
1,999,951
0.16%
1,999,951
3.89%
12/31/2017
1,842,172
0.15%
-2,346,992
8.73%
12/31/2017

About Walvax Biotechnology Co.

View Profile
Address
19/F, Building 9A, Dingyi Tiancheng
Kunming Yunnan 650106
China
Employees -
Website http://www.walvax.com
Updated 07/08/2019
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. Its products include haemophilus influenzae type b conjugate vaccine in vials and pre-encapsulation type; lyophilized type A and C, and ACYW135 meningococcal polysaccharide conjugate vaccine. The company was founded on January 16, 2001 and is headquartered in Kunming, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.